FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

wasimigton,	D.O.	20040	

Check this box if no longer subject to	S
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Shoemaker Daniel D (Last) (First) (Middle) C/O FATE THERAPEUTICS, INC.;						2. Issuer Name and Ticker or Trading Symbol FATE THERAPEUTICS INC [FATE] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director Tother (specify below) 3. Date of Earliest Transaction (Month/Day/Year) 01/20/2021 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director Tother (specify below) Chief Scientific Officer										vner			
3535 GENERAL ATOMICS COURT #200						f Ame	ndment,	Date	of Original	Filed	(Month/D	ay/Year	·)	6. lı	ndividual or	Joint/Grou	p Filing	g (Check Ar	plicable
(Street) SAN DIEGO CA 92121					_								- 1	Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)																
		Tab	le I - No	n-Deri\	ative/	Sec	curitie	s Ac	quired,	Dis	posed o	of, or	Ben	eficial	ly Owne	t			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)						Execution Date,		Transaction Disposed Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 and			Benefic	es ally Following	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(A (C	A) or D)	Price	Transac	Transaction(s) (Instr. 3 and 4)			(
Common stock ⁽¹⁾ 01/20/3					0/2021	1			A		14,41	.1	A	\$0.00	0 98,020			D	
		7	able II -						uired, E s, option						Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,	4. Transa Code (8)		of		Expiration	6. Date Exercisable a Expiration Date (Month/Day/Year)		and 7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v			Date Exercisab		xpiration late			Amount or Number of Shares					
Stock Option (right to	\$109.01	01/20/2021			A		5,481		(2)	0	1/20/2031	Comm Stock		5,481	(3)	5,481	L	D	

Explanation of Responses:

- 1. Award of restricted stock units ("RSUs") that vests with respect to the 1/4th of the underlying shares on each of January 8, 2022, January 8, 2023, January 8, 2024, and January 8, 2025.
- 2. The shares subject to this option shall vest in 48 equal monthly installments beginning on February 1, 2021 such that this option is fully exercisable on January 1, 2025.
- 3. Not applicable.

Remarks:

/s/ Cindy R. Tahl, as Attorney-

01/22/2021

in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.